BioCorRx (BICX) Return on Capital Employed (2011 - 2026)

BioCorRx has disclosed Return on Capital Employed across 16 years of filings, most recently posting 79.96% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 79.96%, up 2827.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 79.96% (up 2827.0% YoY), and the FY2025 annual result was 68.63%, up 313.0% from the prior year.
• Return on Capital Employed came in at 79.96% for Q1 2026 at BioCorRx, down from 143.88% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 147.38% in Q1 2022 to a low of 76.52% in Q3 2025.
• The 5-year median for Return on Capital Employed is 78.3% (2023), against an average of 79.57%.
• Across the five-year window, Return on Capital Employed tumbled 85387 bps in 2022 and jumped 7729 bps in 2025, its largest moves.
• BioCorRx's Return on Capital Employed stood at 102.78% in 2022, then tumbled by 38 bps to 63.45% in 2023, then gained by 5 bps to 66.59% in 2024, then soared by 116 bps to 143.88% in 2025, then plunged by 44 bps to 79.96% in 2026.
• The last three Return on Capital Employed figures came in at 79.96% (Q1 2026), 143.88% (Q4 2025), and 76.52% (Q3 2025), per Business Quant data.